Search

Search Constraints

You searched for: Subject I11 -- I13

Search Results

2. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. (1st January 2021)